Description for medicine or protocol of treatment in detail:
|
Basic treatment: conventional drug treatment, nutrition education and intervention, rehabilitation exercise guidance and training, cognitive function training.
Experimental group: basic treatment + Jiawei Huanshaodan granules, 1 bag/time, bid, take with warm water.
Control group: basic treatment + modified Huanshaodan granules to simulate placebo, 1 bag/time, bid, taken with warm water.
The traditional Chinese medicine granules and placebo for experimental treatment were prepared by Beijing Kangrentang Pharmaceutical Co., Ltd.
Jiawei Huanshaodan Granules: 15 grams of Rehmannia glutinosa, 15 grams of Chinese yam, 10 grams of Achyranthes sichuan, 15 grams of wolfberry, 15 grams of dogwood, 15 grams of Poria, 12 grams of Eucommia, 10 grams of Schisandra, 15 grams of Cistanche, 10 grams of Shichangpu, Morinda officinalis 10 grams, Polygala 10 grams, Atractylodes 15 grams, Codonopsis 15 grams, Fried Divine Comedy 10 grams, Bai Ziren 15 grams.
Placebo: Placebo is prepared according to the requirements of ''General Guidelines for Clinical Research on New Chinese Medicines''. The placebo uses granules with dextrin as the main component, and its dosage, color, usage and dosage are the same as those of "Jiwei Huanshaodan" formula granules. Dextrin is an intermediate product of starch decomposition and has no pharmacological activity.
|
Exclusion criteria:
|
1. Patients with severe cognitive impairment and limited autonomous activities who cannot complete the assessment.
2. Patients in the acute or terminal stage of the disease.
3. Patients with severe cardiovascular and cerebrovascular, digestive system, respiratory system diseases, blood diseases, and malignant tumors.
4. The treatment drugs being received affect the research such as hormones, immunosuppressants, etc.
5. Those who are allergic to the research drug or have sensitive skin.
6. Those who have participated in other clinical trials in the past 3 months.
7. Patients who are deemed unsuitable to participate in clinical trials by the investigator, including those with poor compliance determined by the investigator.
|